MIP Conference

This year’s MIP conference in New York discussed EU decisions relating to FRAND, regulating SEPs in Europe and the application of landmark decisions in the life sciences sector. The forum was attended by industry leading expert-in-house counsel, private practitioners, corporate executives and academics.
Powell Gilbert’s Pete Damerell and Tess Waldron discussed three key decisions from the English courts: the availability of Arrow declarations in FKB and Biogen v Abbvie, the assessment of FRAND licensing offers in Unwired Planet v Huawei and the Supreme Court’s decision in Actavis v Lilly. The full agenda and details of the event can be found here.